As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

bimj1397-sup-0001-S1.pdf30KStatistical Analysis Plan for ADN-01 and ADN-02 entitled: A randomized, double-blind, placebo-controlled, multiregional one-year Phase III study to evaluate the efficacy and safety of Xopenair 100 mcg BID, Xopenair 250 mcg and placebo in adult subjects with AsDyspenathma – can be found in the journal's website.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.